| Min Pa: | Min Pa(max): | Activity's type: |
| Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |
|---|---|---|---|---|---|---|
| 0.913 | 0.002 | 0.913 | Alcohol oxidase inhibitor | 0.082 0.024 DBMET02059 0.171 0.008 DBMET02060 | ||
| 0.832 | 0.001 | 0.832 | Porphobilinogen synthase inhibitor | 0.108 0.032 DBMET02059 0.375 0.004 DBMET02060 | ||
| 0.752 | 0.018 | 0.872 | Caspase 9 stimulant | 0.872 0.004 DBMET02059 0.389 0.117 DBMET02060 | DBMET02059 | |
| 0.725 | 0.003 | 0.725 | Peroxidase inhibitor | 0.153 0.076 DBMET02059 0.472 0.012 DBMET02060 | ||
| 0.632 | 0.005 | 0.632 | GABA C receptor rho-3 antagonist | 0.46 0.038 DBMET02060 | ||
| 0.62 | 0.002 | 0.62 | Phenylalanine 4-hydroxylase inhibitor | 0.081 0.037 DBMET02059 0.179 0.008 DBMET02060 | ||
| 0.581 | 0.018 | 0.581 | Streptokinase A inhibitor | |||
| 0.568 | 0.009 | 0.568 | Amyloid beta aggregation inhibitor | 0.348 0.035 DBMET02059 | ||
| 0.547 | 0.009 | 0.547 | Superoxide dismutase inhibitor | 0.501 0.013 DBMET02060 | ||
| 0.546 | 0.026 | 0.546 | Aldehyde oxidase inhibitor | |||
| 0.521 | 0.004 | 0.521 | Chelator | 0.132 0.044 DBMET02059 0.175 0.029 DBMET02060 | ||
| 0.498 | 0.021 | 0.498 | 12-Lipoxygenase inhibitor | |||
| 0.491 | 0.029 | 0.694 | 5 Hydroxytryptamine release stimulant | 0.694 0.007 DBMET02059 0.198 0.123 DBMET02060 | DBMET02059 | |
| 0.484 | 0.044 | 0.484 | 15-Lipoxygenase inhibitor | 0.23 0.182 DBMET02060 | ||
| 0.457 | 0.026 | 0.457 | Glucose-6-phosphate dehydrogenase-6-phosphogluconolactonase inhibitor | |||
| 0.457 | 0.028 | 0.509 | Caspase 3 stimulant | 0.509 0.019 DBMET02059 | DBMET02059 | |
| 0.468 | 0.041 | 0.468 | Histamine release inhibitor | 0.446 0.052 DBMET02059 0.367 0.092 DBMET02060 | ||
| 0.469 | 0.043 | 0.469 | 5 Hydroxytryptamine release inhibitor | 0.441 0.055 DBMET02059 0.262 0.212 DBMET02060 | ||
| 0.443 | 0.021 | 0.443 | Hypoxia-inducible factor 1 alpha inhibitor | 0.412 0.027 DBMET02059 | ||
| 0.469 | 0.049 | 0.469 | Ca2+/calmodulin-dependent protein kinase kinase A inhibitor | 0.389 0.11 DBMET02060 | ||
| 0.437 | 0.047 | 0.437 | Toll-Like receptor 7 agonist | |||
| 0.433 | 0.048 | 0.433 | Toll-Like receptor agonist | |||
| 0.39 | 0.005 | 0.39 | Heat shock protein 90 alpha antagonist | |||
| 0.404 | 0.02 | 0.404 | Pyruvate kinase inhibitor | |||
| 0.393 | 0.027 | 0.393 | Calcium channel activator | 0.263 0.131 DBMET02060 | ||
| 0.367 | 0.006 | 0.367 | Cystathionine beta-synthase inhibitor | 0.246 0.016 DBMET02059 0.138 0.047 DBMET02060 | ||
| 0.392 | 0.03 | 0.65 | DNA damaging | 0.65 0.006 DBMET02059 0.169 0.146 DBMET02060 | DBMET02059 | |
| 0.41 | 0.052 | 0.533 | Vasodilator, peripheral | 0.533 0.023 DBMET02059 | DBMET02059 | |
| 0.358 | 0.004 | 0.407 | Mannose-6-phosphate isomerase inhibitor | 0.407 0.003 DBMET02059 0.183 0.04 DBMET02060 | DBMET02059 | |
| 0.385 | 0.031 | 0.385 | Antiamyloidogenic | 0.343 0.041 DBMET02059 | ||
| 0.365 | 0.022 | 0.365 | 5 Hydroxytryptamine uptake stimulant | 0.225 0.11 DBMET02060 | ||
| 0.378 | 0.043 | 0.378 | Lipoxygenase inhibitor | |||
| 0.406 | 0.077 | 0.406 | Calcium channel L-type activator | 0.262 0.193 DBMET02059 | ||
| 0.388 | 0.066 | 0.388 | MAP kinase kinase 6 inhibitor | |||
| 0.324 | 0.007 | 0.324 | Heat shock protein 90 antagonist | |||
| 0.328 | 0.012 | 0.554 | Neurotrophic factor enhancer | 0.554 0.003 DBMET02059 0.173 0.107 DBMET02060 | DBMET02059 | |
| 0.35 | 0.035 | 0.35 | Dual specificity tyrosine-phosphorylation regulated kinase 1A inhibitor | |||
| 0.322 | 0.018 | 0.335 | Glyceraldehyde-3-phosphate dehydrogenase inhibitor | 0.335 0.015 DBMET02059 | DBMET02059 | |
| 0.349 | 0.048 | 0.349 | Aryl hydrocarbon receptor agonist | |||
| 0.337 | 0.042 | 0.337 | Ca2+/calmodulin-dependent kinase II alpha inhibitor | |||
| 0.3 | 0.004 | 0.3 | Macrophage migration inhibitory factor inhibitor | 0.072 0.063 DBMET02060 | ||
| 0.3 | 0.005 | 0.3 | Alcohol dehydrogenase inhibitor | 0.243 0.008 DBMET02059 | ||
| 0.32 | 0.025 | 0.32 | Tyrosine 3 hydroxylase inhibitor | 0.195 0.146 DBMET02060 | ||
| 0.303 | 0.011 | 0.371 | Nitric-oxide synthase stimulant | 0.371 0.004 DBMET02059 0.199 0.091 DBMET02060 | DBMET02059 | |
| 0.333 | 0.042 | 0.333 | Dyrk kinase inhibitor | |||
| 0.331 | 0.044 | 0.559 | Free radical scavenger | 0.559 0.011 DBMET02059 | DBMET02059 | |
| 0.345 | 0.066 | 0.707 | Cholesterol antagonist | 0.707 0.008 DBMET02059 0.27 0.111 DBMET02060 | DBMET02059 | |
| 0.291 | 0.02 | 0.291 | Tumour necrosis factor antagonist | |||
| 0.278 | 0.007 | 0.278 | GABA C receptor rho-2 antagonist | 0.171 0.05 DBMET02060 | ||
| 0.28 | 0.021 | 0.533 | NOS3 expression enhancer | 0.533 0.005 DBMET02059 | DBMET02059 | |
| 0.257 | 0.005 | 0.257 | Creatine kinase inhibitor | 0.11 0.049 DBMET02060 | ||
| 0.293 | 0.045 | 0.493 | Cyclic AMP phosphodiesterase inhibitor | 0.493 0.007 DBMET02059 | DBMET02059 | |
| 0.247 | 0.006 | 0.247 | NAD(P)H dehydrogenase (quinone) inhibitor | |||
| 0.298 | 0.059 | 0.298 | Insulysin inhibitor | |||
| 0.244 | 0.014 | 0.244 | GABA C receptor agonist | 0.098 0.069 DBMET02060 | ||
| 0.273 | 0.044 | 0.273 | MAP kinase kinase 2 inhibitor | |||
| 0.267 | 0.041 | 0.433 | RNA-directed DNA polymerase inhibitor | 0.433 0.015 DBMET02059 0.238 0.058 DBMET02060 | DBMET02059 | |
| 0.358 | 0.134 | 0.628 | Apoptosis agonist | 0.628 0.043 DBMET02059 0.287 0.182 DBMET02060 | DBMET02059 | |
| 0.264 | 0.044 | 0.363 | Anesthetic general | 0.363 0.022 DBMET02059 | DBMET02059 | |
| 0.332 | 0.113 | 0.637 | Antibacterial | 0.637 0.014 DBMET02059 0.266 0.163 DBMET02060 | DBMET02059 | |
| 0.261 | 0.042 | 0.292 | DNA methyltransferase I inhibitor | 0.292 0.029 DBMET02059 | DBMET02059 | |
| 0.22 | 0.006 | 0.417 | Mannitol-1-phosphate 5-dehydrogenase inhibitor | 0.417 0.002 DBMET02059 0.098 0.015 DBMET02060 | DBMET02059 | |
| 0.214 | 0.003 | 0.214 | Granulocyte macrophage colony stimulating factor agonist | 0.087 0.057 DBMET02059 0.138 0.008 DBMET02060 | ||
| 0.226 | 0.015 | 0.226 | Bronchodilator | |||
| 0.269 | 0.059 | 0.269 | Gastrin inhibitor | 0.231 0.104 DBMET02059 | ||
| 0.255 | 0.046 | 0.34 | DNA methylase inhibitor | 0.34 0.018 DBMET02059 | DBMET02059 | |
| 0.301 | 0.093 | 0.603 | Transcription factor NF kappa B inhibitor | 0.603 0.031 DBMET02059 | DBMET02059 | |
| 0.277 | 0.071 | 0.635 | Antioxidant | 0.635 0.009 DBMET02059 0.217 0.103 DBMET02060 | DBMET02059 | |
| 0.227 | 0.022 | 0.336 | Aldehyde dehydrogenase inhibitor | 0.336 0.009 DBMET02059 | DBMET02059 | |
| 0.213 | 0.01 | 0.213 | Phosphodiesterase 4D inhibitor | |||
| 0.23 | 0.028 | 0.283 | Topoisomerase II inhibitor | 0.283 0.02 DBMET02059 | DBMET02059 | |
| 0.224 | 0.027 | 0.224 | M18 aspartyl aminopeptidase inhibitor | |||
| 0.238 | 0.041 | 0.238 | Dual specificity phosphatase inhibitor | 0.208 0.051 DBMET02060 | ||
| 0.244 | 0.048 | 0.244 | Dual specificity tyrosine-phosphorylation regulated kinase 3 inhibitor | |||
| 0.239 | 0.044 | 0.239 | MAP kinase kinase 3 inhibitor | 0.216 0.081 DBMET02060 | ||
| 0.226 | 0.032 | 0.226 | Succinate dehydrogenase inhibitor | 0.138 0.136 DBMET02060 | ||
| 0.214 | 0.022 | 0.237 | DNA intercalator | 0.237 0.018 DBMET02059 0.116 0.06 DBMET02060 | DBMET02059 | |
| 0.239 | 0.048 | 0.394 | Non-steroidal antiinflammatory agent | 0.394 0.014 DBMET02059 | DBMET02059 | |
| 0.219 | 0.027 | 0.219 | Alkaline phosphatase inhibitor | 0.153 0.058 DBMET02059 0.172 0.046 DBMET02060 | ||
| 0.214 | 0.023 | 0.343 | Topoisomerase I inhibitor | 0.343 0.008 DBMET02059 | DBMET02059 | |
| 0.217 | 0.027 | 0.465 | Hexokinase inhibitor | 0.465 0.003 DBMET02059 | DBMET02059 | |
| 0.206 | 0.018 | 0.206 | CF transmembrane conductance regulator agonist | 0.202 0.02 DBMET02059 | ||
| 0.193 | 0.008 | 0.193 | Heat shock protein 70 antagonist | 0.183 0.01 DBMET02059 | ||
| 0.205 | 0.02 | 0.205 | Aminopeptidase B inhibitor | 0.179 0.027 DBMET02060 | ||
| 0.231 | 0.047 | 0.231 | Dual specificity phosphatase 3 inhibitor | 0.21 0.056 DBMET02060 | ||
| 0.195 | 0.013 | 0.277 | Gastric antisecretory | 0.277 0.005 DBMET02060 | DBMET02060 | |
| 0.184 | 0.004 | 0.184 | Botulinum neurotoxin type A inhibitor | 0.062 0.035 DBMET02060 | ||
| 0.186 | 0.009 | 0.186 | CYP2A6 inhibitor | 0.108 0.032 DBMET02060 | ||
| 0.277 | 0.101 | 0.277 | Sodium/bile acid cotransporter inhibitor | |||
| 0.178 | 0.004 | 0.178 | Aconitate hydratase inhibitor | 0.089 0.011 DBMET02060 | ||
| 0.318 | 0.145 | 0.318 | Transcription factor inhibitor | |||
| 0.187 | 0.014 | 0.366 | Beta glucuronidase inhibitor | 0.366 0.004 DBMET02059 0.125 0.041 DBMET02060 | DBMET02059 | |
| 0.321 | 0.149 | 0.596 | Alpha-glucosidase inhibitor | 0.596 0.055 DBMET02059 | DBMET02059 | |
| 0.213 | 0.043 | 0.213 | 5 Hydroxytryptamine 3E antagonist | 0.21 0.048 DBMET02060 | ||
| 0.183 | 0.017 | 0.183 | GABA C receptor antagonist | 0.116 0.057 DBMET02060 | ||
| 0.2 | 0.033 | 0.2 | Arachidonic acid antagonist | |||
| 0.178 | 0.012 | 0.178 | GABA C receptor rho-1 antagonist | 0.092 0.075 DBMET02060 | ||
| 0.179 | 0.016 | 0.197 | TRPA1 agonist | 0.11 0.071 DBMET02059 0.197 0.011 DBMET02060 | DBMET02060 | |
| 0.321 | 0.158 | 0.321 | MAP kinase 1 inhibitor | |||
| 0.196 | 0.035 | 0.487 | Alpha-N-acetylglucosaminidase inhibitor | 0.487 0.005 DBMET02059 | DBMET02059 | |
| 0.182 | 0.022 | 0.182 | Carbonic anhydrase XV inhibitor | 0.108 0.057 DBMET02060 | ||
| 0.217 | 0.057 | 0.217 | I kappa B kinase epsilon inhibitor | |||
| 0.177 | 0.019 | 0.177 | Activin receptor-like kinase 4 inhibitor | |||
| 0.235 | 0.078 | 0.488 | DNA synthesis inhibitor | 0.488 0.014 DBMET02059 | DBMET02059 | |
| 0.213 | 0.057 | 0.213 | LIM domain kinase 1 inhibitor | |||
| 0.18 | 0.024 | 0.299 | Xanthine oxidase inhibitor | 0.299 0.008 DBMET02059 | DBMET02059 | |
| 0.177 | 0.022 | 0.475 | UDP-glucose 4-epimerase inhibitor | 0.475 0.003 DBMET02059 | DBMET02059 | |
| 0.194 | 0.038 | 0.194 | Neurotensin receptor agonist | |||
| 0.158 | 0.004 | 0.158 | Catechol O-methyltransferase inhibitor | 0.036 0.018 DBMET02060 | ||
| 0.24 | 0.086 | 0.24 | 5 Hydroxytryptamine 1E antagonist | 0.235 0.091 DBMET02060 | ||
| 0.185 | 0.032 | 0.185 | MAO A inhibitor | |||
| 0.173 | 0.021 | 0.173 | Potassium channel (Ca-activated) activator | |||
| 0.197 | 0.045 | 0.738 | Amylase inhibitor | 0.738 0.003 DBMET02059 | DBMET02059 | |
| 0.162 | 0.01 | 0.162 | Histamine N-methyltransferase inhibitor | 0.122 0.029 DBMET02060 | ||
| 0.194 | 0.043 | 0.288 | ATPase inhibitor | 0.288 0.007 DBMET02059 | DBMET02059 | |
| 0.167 | 0.017 | 0.167 | Histidine decarboxylase inhibitor | |||
| 0.169 | 0.018 | 0.169 | Phosphodiesterase IV inhibitor | |||
| 0.16 | 0.012 | 0.178 | Acetylcholine release stimulant | 0.111 0.064 DBMET02059 0.178 0.006 DBMET02060 | DBMET02060 | |
| 0.163 | 0.015 | 0.163 | DOPA decarboxylase inhibitor | |||
| 0.167 | 0.02 | 0.211 | Topoisomerase II alpha inhibitor | 0.211 0.014 DBMET02059 0.08 0.053 DBMET02060 | DBMET02059 | |
| 0.159 | 0.012 | 0.168 | HIV-1 integrase (Strand Transfer) inhibitor | 0.076 0.033 DBMET02059 0.168 0.011 DBMET02060 | DBMET02060 | |
| 0.206 | 0.061 | 0.206 | Histone acetyltransferase inhibitor | |||
| 0.167 | 0.022 | 0.745 | Mediator release inhibitor | 0.745 0.003 DBMET02059 | DBMET02059 | |
| 0.204 | 0.059 | 0.204 | Growth factor agonist | 0.182 0.083 DBMET02059 | ||
| 0.153 | 0.008 | 0.153 | HIV-1 integrase inhibitor | 0.134 0.011 DBMET02060 | ||
| 0.264 | 0.121 | 0.544 | Vasodilator, coronary | 0.544 0.011 DBMET02059 | DBMET02059 | |
| 0.167 | 0.024 | 0.167 | Interleukin 8 antagonist | |||
| 0.146 | 0.005 | 0.146 | Potassium channel (ATP-sensitive) blocker | 0.063 0.055 DBMET02060 | ||
| 0.161 | 0.022 | 0.161 | Ca2+-transporting ATPase inhibitor | 0.146 0.054 DBMET02059 | ||
| 0.16 | 0.022 | 0.16 | HIV-1 integrase (Overall Integration) inhibitor | |||
| 0.162 | 0.024 | 0.162 | Carbonic anhydrase III inhibitor | 0.148 0.029 DBMET02059 0.113 0.05 DBMET02060 | ||
| 0.161 | 0.024 | 0.161 | Antineoplastic alkaloid | |||
| 0.164 | 0.028 | 0.164 | 5 Hydroxytryptamine 3A agonist | |||
| 0.184 | 0.049 | 0.184 | Death-associated protein kinase 2 inhibitor | |||
| 0.139 | 0.005 | 0.205 | H+/K+-transporting ATPase inhibitor | 0.049 0.038 DBMET02059 0.205 0.004 DBMET02060 | DBMET02060 | |
| 0.136 | 0.004 | 0.136 | Glutamate (mGluR7) antagonist | 0.094 0.014 DBMET02060 | ||
| 0.182 | 0.052 | 0.182 | Dual specificity tyrosine-phosphorylation regulated kinase 1B inhibitor | |||
| 0.163 | 0.033 | 0.163 | 5-Lipoxygenase inhibitor | |||
| 0.169 | 0.04 | 0.418 | Monophenol monooxygenase inhibitor | 0.418 0.011 DBMET02059 | DBMET02059 | |
| 0.179 | 0.051 | 0.285 | Lipid peroxidase inhibitor | 0.285 0.021 DBMET02059 | DBMET02059 | |
| 0.141 | 0.015 | 0.141 | Lanosterol 14 alpha demethylase inhibitor | 0.097 0.06 DBMET02059 | ||
| 0.166 | 0.04 | 0.166 | Adenylate cyclase stimulant | 0.16 0.048 DBMET02059 0.162 0.044 DBMET02060 | ||
| 0.154 | 0.029 | 0.299 | Photosensitizer | 0.299 0.004 DBMET02059 | DBMET02059 | |
| 0.164 | 0.039 | 0.346 | Alkylator | 0.346 0.01 DBMET02059 0.1 0.089 DBMET02060 | DBMET02059 | |
| 0.142 | 0.017 | 0.142 | Toll-Like receptor 3 antagonist | 0.117 0.031 DBMET02060 | ||
| 0.164 | 0.039 | 0.164 | MAP kinase kinase 4 inhibitor | |||
| 0.128 | 0.005 | 0.128 | Heat shock protein 90 beta antagonist | |||
| 0.161 | 0.039 | 0.161 | Glycogen synthase kinase-3 beta inhibitor | |||
| 0.177 | 0.055 | 0.177 | Cyclin-dependent kinase 8 inhibitor | |||
| 0.175 | 0.054 | 0.175 | Cyclin-dependent kinase 3 inhibitor | |||
| 0.161 | 0.042 | 0.161 | Nav1.6 sodium channel blocker | |||
| 0.15 | 0.031 | 0.321 | DNA repair enzyme inhibitor | 0.321 0.004 DBMET02059 | DBMET02059 | |
| 0.146 | 0.028 | 0.146 | CC chemokine 6 receptor antagonist | 0.138 0.046 DBMET02059 | ||
| 0.133 | 0.016 | 0.135 | HIV-1 integrase (3'-Processing) inhibitor | 0.066 0.042 DBMET02059 0.135 0.016 DBMET02060 | DBMET02060 | |
| 0.171 | 0.054 | 0.171 | CDC-like kinase 1 inhibitor | |||
| 0.169 | 0.053 | 0.169 | Activin receptor-like kinase 2 inhibitor | |||
| 0.134 | 0.019 | 0.134 | Dual specificity tyrosine-phosphorylation regulated kinase 2 inhibitor | |||
| 0.121 | 0.007 | 0.121 | Topoisomerase II beta inhibitor | 0.091 0.011 DBMET02059 | ||
| 0.124 | 0.01 | 0.124 | CDC25B inhibitor | 0.061 0.049 DBMET02059 | ||
| 0.123 | 0.011 | 0.123 | Purinergic P2X1 antagonist | |||
| 0.121 | 0.01 | 0.121 | Maillard reaction inhibitor | |||
| 0.115 | 0.004 | 0.115 | Transcription factor RelA inhibitor | 0.088 0.011 DBMET02060 | ||
| 0.176 | 0.065 | 0.176 | Phospholipase C inhibitor | 0.155 0.096 DBMET02059 0.155 0.096 DBMET02060 | ||
| 0.141 | 0.031 | 0.141 | Transcription factor STAT6 inhibitor | |||
| 0.154 | 0.043 | 0.154 | Cathepsin H inhibitor | 0.105 0.098 DBMET02060 | ||
| 0.19 | 0.08 | 0.19 | Death-associated protein kinase 3 inhibitor | |||
| 0.155 | 0.045 | 0.185 | Pregnane X receptor agonist | 0.185 0.016 DBMET02060 | DBMET02060 | |
| 0.147 | 0.039 | 0.147 | Ferrochelatase inhibitor | |||
| 0.156 | 0.049 | 0.156 | Toll-Like receptor 2 antagonist | |||
| 0.163 | 0.057 | 0.163 | Glycogen synthase kinase-3 alpha inhibitor | |||
| 0.13 | 0.024 | 0.397 | NADH dehydrogenase inhibitor | 0.397 0.005 DBMET02059 | DBMET02059 | |
| 0.157 | 0.051 | 0.157 | Toll-Like receptor antagonist | 0.108 0.106 DBMET02059 | ||
| 0.142 | 0.037 | 0.142 | Protein kinase C gamma inhibitor | |||
| 0.165 | 0.061 | 0.38 | Interferon gamma antagonist | 0.38 0.012 DBMET02059 | DBMET02059 | |
| 0.113 | 0.009 | 0.113 | AMPA receptor antagonist | |||
| 0.123 | 0.019 | 0.123 | Phosphodiesterase XI inhibitor | 0.078 0.064 DBMET02060 | ||
| 0.123 | 0.019 | 0.123 | Phosphodiesterase 11A inhibitor | 0.078 0.064 DBMET02060 | ||
| 0.243 | 0.139 | 0.243 | Thioredoxin glutathione reductase inhibitor | |||
| 0.159 | 0.055 | 0.159 | MAP kinase 3 inhibitor | |||
| 0.133 | 0.03 | 0.133 | Prolactin inhibitor | |||
| 0.125 | 0.023 | 0.125 | Adrenaline agonist | |||
| 0.148 | 0.046 | 0.148 | Glycogen synthase kinase-3 inhibitor | |||
| 0.173 | 0.071 | 0.173 | 3C-like protease (Human coronavirus) inhibitor | |||
| 0.118 | 0.017 | 0.118 | Potassium channel large-conductance Ca-activated activator | |||
| 0.211 | 0.111 | 0.485 | Interleukin agonist | 0.485 0.01 DBMET02059 | DBMET02059 | |
| 0.127 | 0.028 | 0.145 | Protein kinase C zeta inhibitor | 0.145 0.021 DBMET02060 | DBMET02060 | |
| 0.132 | 0.035 | 0.132 | Adenylate kinase inhibitor | 0.11 0.053 DBMET02059 | ||
| 0.156 | 0.059 | 0.156 | Toll-Like receptor 9 antagonist | |||
| 0.124 | 0.028 | 0.124 | Estrogen receptor beta antagonist | |||
| 0.162 | 0.067 | 0.453 | Melanin inhibitor | 0.453 0.009 DBMET02059 | DBMET02059 | |
| 0.106 | 0.01 | 0.106 | S-adenosyl-L-methionine decarboxylase inhibitor | 0.082 0.034 DBMET02060 | ||
| 0.145 | 0.05 | 0.154 | Antibacterial (Helicobacter pylori) | 0.129 0.068 DBMET02059 0.154 0.043 DBMET02060 | DBMET02060 | |
| 0.13 | 0.036 | 0.13 | Pim-1 kinase inhibitor | |||
| 0.104 | 0.01 | 0.104 | Fatty acid synthase inhibitor | 0.067 0.028 DBMET02059 | ||
| 0.115 | 0.021 | 0.115 | Aminopeptidase I inhibitor | 0.066 0.059 DBMET02060 | ||
| 0.112 | 0.018 | 0.112 | D-Ala-D-Ala ligase inhibitor | |||
| 0.106 | 0.014 | 0.106 | Xanthine dehydrogenase inhibitor | 0.056 0.041 DBMET02059 | ||
| 0.129 | 0.039 | 0.129 | Estrogen antagonist | |||
| 0.153 | 0.063 | 0.282 | Cell wall synthesis inhibitor | 0.282 0.011 DBMET02059 0.207 0.027 DBMET02060 | DBMET02059 | |
| 0.123 | 0.034 | 0.123 | Electrolyte absorption antagonist | |||
| 0.113 | 0.024 | 0.113 | Keratolytic | |||
| 0.215 | 0.126 | 0.215 | Ca2+/calmodulin-dependent kinase IV inhibitor | |||
| 0.1 | 0.013 | 0.1 | MAP kinase kinase 7 inhibitor | |||
| 0.144 | 0.058 | 0.144 | NADPH oxidase inhibitor | |||
| 0.113 | 0.028 | 0.138 | Glutamate release inhibitor | 0.138 0.013 DBMET02059 | DBMET02059 | |
| 0.118 | 0.033 | 0.347 | Triose-phosphate isomerase inhibitor | 0.347 0.004 DBMET02059 0.156 0.018 DBMET02060 | DBMET02059 | |
| 0.209 | 0.125 | 0.209 | Transcription factor STAT inhibitor | |||
| 0.148 | 0.064 | 0.148 | Sphingosine 1-phosphate receptor 5 antagonist | |||
| 0.145 | 0.061 | 0.145 | Phosphodiesterase inhibitor | |||
| 0.147 | 0.065 | 0.147 | Histone deacetylase SIRT1 inhibitor | |||
| 0.107 | 0.026 | 0.107 | mTOR complex 2 inhibitor | |||
| 0.113 | 0.032 | 0.279 | Phosphodiesterase 6D inhibitor | 0.279 0.003 DBMET02059 0.096 0.061 DBMET02060 | DBMET02059 | |
| 0.2 | 0.119 | 0.249 | Spasmolytic | 0.249 0.092 DBMET02059 | DBMET02059 | |
| 0.107 | 0.026 | 0.107 | Glutamate decarboxylase inhibitor | |||
| 0.117 | 0.038 | 0.117 | Interleukin 1 beta converting enzyme inhibitor | |||
| 0.129 | 0.049 | 0.129 | GABA receptor agonist | |||
| 0.097 | 0.019 | 0.097 | GABA B receptor agonist | |||
| 0.132 | 0.053 | 0.132 | Sphingosine 1-phosphate receptor 4 antagonist | |||
| 0.102 | 0.025 | 0.102 | Leukotriene synthesis inhibitor | |||
| 0.141 | 0.065 | 0.141 | MAO inhibitor | |||
| 0.113 | 0.037 | 0.113 | Potassium channel activator | |||
| 0.09 | 0.014 | 0.09 | Phosphodiesterase 1C inhibitor | |||
| 0.112 | 0.036 | 0.112 | Pim-3 kinase inhibitor | |||
| 0.1 | 0.025 | 0.1 | Estrogen-related receptor beta agonist | |||
| 0.114 | 0.04 | 0.114 | Hepatocyte growth factor antagonist | |||
| 0.14 | 0.066 | 0.14 | Interleukin 1 antagonist | |||
| 0.093 | 0.019 | 0.093 | 5 Hydroxytryptamine 3 agonist | |||
| 0.091 | 0.017 | 0.091 | Beta 3 adrenoreceptor antagonist | |||
| 0.13 | 0.057 | 0.13 | Cholesterol synthesis inhibitor | 0.13 0.057 DBMET02060 | ||
| 0.086 | 0.014 | 0.086 | 3(or 17)beta-hydroxysteroid dehydrogenase inhibitor | |||
| 0.129 | 0.058 | 0.16 | Beta amyloid protein antagonist | 0.16 0.034 DBMET02059 | DBMET02059 | |
| 0.107 | 0.037 | 0.107 | Phosphodiesterase I inhibitor | |||
| 0.168 | 0.099 | 0.168 | Clk dual-specificity kinase inhibitor | |||
| 0.147 | 0.079 | 0.147 | Dual specificity tyrosine-phosphorylation-regulated kinase 4 inhibitor | |||
| 0.074 | 0.006 | 0.074 | Alpha 1d adrenoreceptor agonist | |||
| 0.074 | 0.006 | 0.074 | Dopamine beta hydroxylase inhibitor | |||
| 0.083 | 0.016 | 0.083 | Beta 1 adrenoreceptor antagonist | |||
| 0.111 | 0.044 | 0.111 | MAP kinase kinase 1 inhibitor | |||
| 0.135 | 0.069 | 0.135 | Death-associated protein kinase 1 inhibitor | |||
| 0.087 | 0.021 | 0.087 | Aryl hydrocarbon receptor antagonist | |||
| 0.144 | 0.08 | 0.144 | Cytidine deaminase inhibitor | |||
| 0.11 | 0.046 | 0.228 | UDP-N-acetylglucosamine 1-carboxyvinyltransferase inhibitor | 0.228 0.012 DBMET02059 | DBMET02059 | |
| 0.094 | 0.03 | 0.094 | Alpha adrenoreceptor agonist | |||
| 0.085 | 0.021 | 0.085 | Alpha 2 adrenoreceptor agonist | |||
| 0.096 | 0.033 | 0.096 | Caspase 7 inhibitor | |||
| 0.095 | 0.034 | 0.27 | Phosphofructokinase-1 inhibitor | 0.27 0.006 DBMET02059 | DBMET02059 | |
| 0.108 | 0.046 | 0.121 | Uric acid excretion stimulant | 0.121 0.038 DBMET02059 | DBMET02059 | |
| 0.098 | 0.037 | 0.098 | Myeloperoxidase inhibitor | |||
| 0.075 | 0.014 | 0.075 | Beta 2 adrenoreceptor antagonist | |||
| 0.072 | 0.012 | 0.072 | Pregnane X receptor antagonist | |||
| 0.131 | 0.07 | 0.166 | Interleukin 4 antagonist | 0.166 0.037 DBMET02059 | DBMET02059 | |
| 0.197 | 0.137 | 0.197 | Transcription factor STAT3 inhibitor | |||
| 0.119 | 0.059 | 0.119 | Cyclin-dependent kinase 5 inhibitor | |||
| 0.144 | 0.084 | 0.144 | Ca2+/calmodulin-dependent protein kinase kinase B inhibitor | |||
| 0.089 | 0.029 | 0.089 | Glycine receptor agonist | |||
| 0.127 | 0.068 | 0.127 | Glutamate receptor antagonist | |||
| 0.109 | 0.051 | 0.109 | Anabolic | 0.092 0.075 DBMET02060 | ||
| 0.068 | 0.009 | 0.068 | Dopamine D5 agonist | |||
| 0.094 | 0.036 | 0.094 | Nicotinic alpha4beta2 receptor antagonist | |||
| 0.063 | 0.005 | 0.063 | Methionyl aminopeptidase 2 inhibitor | |||
| 0.123 | 0.066 | 0.123 | MAP kinase 12 inhibitor | |||
| 0.062 | 0.005 | 0.062 | Protocollagen prolyl hydroxylase inhibitor | |||
| 0.08 | 0.023 | 0.08 | Phosphodiesterase 1B inhibitor | |||
| 0.167 | 0.111 | 0.172 | Insulin sensitizer | 0.172 0.104 DBMET02059 | DBMET02059 | |
| 0.084 | 0.028 | 0.085 | Phospholipase D inhibitor | 0.085 0.027 DBMET02060 | DBMET02060 | |
| 0.087 | 0.032 | 0.087 | Amidase inhibitor | |||
| 0.071 | 0.017 | 0.071 | Potassium channel (Inward rectifier) blocker | |||
| 0.08 | 0.027 | 0.08 | Beta adrenoreceptor antagonist | |||
| 0.058 | 0.005 | 0.058 | Vanilloid 3 antagonist | |||
| 0.068 | 0.016 | 0.068 | Glutamate (mGluR group III) agonist | |||
| 0.095 | 0.043 | 0.095 | GABA A receptor agonist | |||
| 0.063 | 0.011 | 0.063 | Liver X receptor alpha agonist | |||
| 0.055 | 0.003 | 0.055 | Egl nine homolog 1 inhibitor | |||
| 0.069 | 0.017 | 0.069 | Dopamine D2 agonist | |||
| 0.123 | 0.071 | 0.123 | MAP kinase kinase inhibitor | |||
| 0.072 | 0.021 | 0.072 | Dihydroorotate dehydrogenase inhibitor | |||
| 0.074 | 0.023 | 0.074 | Cyclin D1 inhibitor | |||
| 0.088 | 0.037 | 0.088 | Estrogen receptor alpha antagonist | |||
| 0.062 | 0.012 | 0.062 | Geranyltranstransferase inhibitor | |||
| 0.107 | 0.058 | 0.107 | Protein kinase (CK2) inhibitor | |||
| 0.108 | 0.058 | 0.108 | Urease inhibitor | |||
| 0.07 | 0.02 | 0.176 | Factor IXa inhibitor | 0.079 0.016 DBMET02059 0.176 0.003 DBMET02060 | DBMET02060 | |
| 0.129 | 0.08 | 0.129 | Cytokine production inhibitor | |||
| 0.177 | 0.129 | 0.476 | Tumour necrosis factor alpha release inhibitor | 0.476 0.016 DBMET02059 0.193 0.115 DBMET02060 | DBMET02059 | |
| 0.054 | 0.006 | 0.054 | CF transmembrane conductance regulator antagonist | |||
| 0.157 | 0.11 | 0.157 | Psychostimulant | |||
| 0.098 | 0.051 | 0.196 | Thioredoxin inhibitor | 0.196 0.009 DBMET02059 | DBMET02059 | |
| 0.092 | 0.045 | 0.092 | Carbonic anhydrase VI inhibitor | 0.084 0.052 DBMET02059 | ||
| 0.076 | 0.03 | 0.076 | Aromatase inhibitor | |||
| 0.075 | 0.029 | 0.075 | Biliverdin reductase inhibitor | |||
| 0.065 | 0.018 | 0.065 | CD45 antagonist | |||
| 0.06 | 0.014 | 0.06 | Urate transporter 1 inhibitor | |||
| 0.059 | 0.013 | 0.072 | Guanylate cyclase inhibitor | 0.072 0.004 DBMET02059 0.055 0.016 DBMET02060 | DBMET02059 | |
| 0.082 | 0.036 | 0.082 | Dopamine agonist | |||
| 0.063 | 0.018 | 0.063 | Immunoglobulin Fc receptor antagonist | |||
| 0.055 | 0.01 | 0.055 | 3-Hydroxyanthranilate 3,4-dioxygenase inhibitor | |||
| 0.051 | 0.009 | 0.051 | Free fatty acid receptor 1 antagonist | |||
| 0.09 | 0.049 | 0.09 | MAP-kinase-activated kinase inhibitor | |||
| 0.068 | 0.027 | 0.068 | Phosphodiesterase 1A inhibitor | |||
| 0.086 | 0.046 | 0.107 | CC chemokine 5 receptor agonist | 0.107 0.015 DBMET02060 | DBMET02060 | |
| 0.068 | 0.029 | 0.081 | Carbonic anhydrase VB inhibitor | 0.081 0.022 DBMET02060 | DBMET02060 | |
| 0.082 | 0.043 | 0.082 | Glutamate dehydrogenase inhibitor | |||
| 0.055 | 0.016 | 0.055 | Glutamate (mGluR group III) antagonist | |||
| 0.056 | 0.018 | 0.056 | Purinergic P2X4 antagonist | |||
| 0.133 | 0.095 | 0.133 | Neuropeptide Y1 antagonist | |||
| 0.071 | 0.034 | 0.071 | Carbamoyl phosphate synthetase inhibitor | 0.057 0.046 DBMET02059 | ||
| 0.196 | 0.159 | 0.196 | Prostaglandin dehydrogenase inhibitor | |||
| 0.075 | 0.038 | 0.075 | Protein kinase C beta inhibitor | |||
| 0.086 | 0.049 | 0.086 | Acetylcholine nicotinic agonist | |||
| 0.1 | 0.063 | 0.1 | Cyclin-dependent kinase 9 inhibitor | |||
| 0.08 | 0.044 | 0.189 | Histone deacetylase stimulant | 0.189 0.005 DBMET02059 | DBMET02059 | |
| 0.08 | 0.044 | 0.189 | Histone deacetylase SIRT1 stimulant | 0.189 0.005 DBMET02059 | DBMET02059 | |
| 0.121 | 0.086 | 0.158 | Vanilloid 1 agonist | 0.158 0.031 DBMET02059 0.138 0.053 DBMET02060 | DBMET02059 | |
| 0.056 | 0.021 | 0.056 | NMDA receptor subunit 3B antagonist | |||
| 0.074 | 0.04 | 0.074 | Phosphodiesterase 4B inhibitor | |||
| 0.066 | 0.032 | 0.066 | Argininosuccinate synthase inhibitor | |||
| 0.063 | 0.029 | 0.063 | Ryanodine receptor antagonist | |||
| 0.046 | 0.012 | 0.046 | Glutamate (mGluR4) agonist | |||
| 0.09 | 0.056 | 0.09 | Bromodomain-containing protein 2 inhibitor | |||
| 0.141 | 0.108 | 0.141 | CDC-like kinase 4 inhibitor | |||
| 0.102 | 0.068 | 0.222 | AMP-activated protein kinase stimulant | 0.222 0.008 DBMET02059 | DBMET02059 | |
| 0.097 | 0.063 | 0.153 | Sphingomyelinase inhibitor | 0.153 0.023 DBMET02059 | DBMET02059 | |
| 0.129 | 0.096 | 0.129 | Acetylcholine M1 receptor antagonist | |||
| 0.068 | 0.035 | 0.068 | NMDA 2C receptor antagonist | |||
| 0.043 | 0.01 | 0.043 | Protein kinase (CK2) beta inhibitor | |||
| 0.066 | 0.034 | 0.093 | 3-Oxoacyl-[acyl-carrier-protein] synthase inhibitor | 0.093 0.019 DBMET02059 | DBMET02059 | |
| 0.065 | 0.032 | 0.065 | Beta 2 adrenoreceptor agonist | |||
| 0.062 | 0.03 | 0.062 | Sphingosine kinase 2 inhibitor | |||
| 0.136 | 0.105 | 0.136 | Mcl-1 antagonist | |||
| 0.043 | 0.012 | 0.043 | Tubulin agonist | |||
| 0.049 | 0.019 | 0.049 | Nerve growth factor antagonist | |||
| 0.041 | 0.011 | 0.041 | Methionyl aminopeptidase 1 inhibitor | |||
| 0.098 | 0.069 | 0.098 | Hedgehog signaling inhibitor | |||
| 0.128 | 0.099 | 0.378 | Hemostatic | 0.378 0.009 DBMET02059 0.269 0.019 DBMET02060 | DBMET02059 | |
| 0.083 | 0.054 | 0.083 | Transforming growth factor beta 3 antagonist | |||
| 0.052 | 0.024 | 0.086 | Cytokine production stimulant | 0.086 0.005 DBMET02059 | DBMET02059 | |
| 0.076 | 0.048 | 0.084 | Adenosine A3 receptor antagonist | 0.084 0.038 DBMET02059 | DBMET02059 | |
| 0.056 | 0.028 | 0.056 | CXC chemokine 1 receptor antagonist | |||
| 0.058 | 0.031 | 0.058 | Lysine-specific demethylase 1A inhibitor | |||
| 0.048 | 0.021 | 0.048 | Histamine H1 receptor agonist | 0.041 0.037 DBMET02060 | ||
| 0.053 | 0.026 | 0.13 | Glucose-6-phosphate isomerase inhibitor | 0.13 0.003 DBMET02059 | DBMET02059 | |
| 0.093 | 0.067 | 0.093 | Bile acid receptor antagonist | |||
| 0.07 | 0.044 | 0.07 | Exportin-1 inhibitor | |||
| 0.075 | 0.049 | 0.103 | CDC25A inhibitor | 0.103 0.026 DBMET02060 | DBMET02060 | |
| 0.048 | 0.023 | 0.048 | Beta adrenoreceptor agonist | |||
| 0.075 | 0.051 | 0.075 | Catalase inhibitor | 0.071 0.054 DBMET02060 | ||
| 0.045 | 0.02 | 0.047 | TRPM8 blocker | 0.047 0.018 DBMET02060 | DBMET02060 | |
| 0.029 | 0.004 | 0.029 | Nicotinic acid receptor 1 antagonist | |||
| 0.063 | 0.039 | 0.063 | TRPA1 antagonist | |||
| 0.051 | 0.026 | 0.051 | Oleamide hydrolase inhibitor | |||
| 0.073 | 0.049 | 0.073 | NMDA 2 receptor antagonist | |||
| 0.052 | 0.029 | 0.075 | Adenosine deaminase inhibitor | 0.075 0.011 DBMET02059 | DBMET02059 | |
| 0.074 | 0.051 | 0.074 | MAP-kinase-activated kinase 2 inhibitor | |||
| 0.036 | 0.013 | 0.036 | Nicotinic alpha3beta4 receptor agonist | |||
| 0.026 | 0.004 | 0.026 | Granulocyte colony stimulating factor receptor agonist | 0.02 0.008 DBMET02060 | ||
| 0.057 | 0.035 | 0.057 | Pim-2 kinase inhibitor | |||
| 0.034 | 0.012 | 0.043 | Kynurenine 3 monooxygenase inhibitor | 0.043 0.009 DBMET02060 | DBMET02060 | |
| 0.056 | 0.034 | 0.056 | Thromboxane synthase inhibitor | |||
| 0.048 | 0.026 | 0.048 | Dihydroorotase inhibitor | |||
| 0.074 | 0.052 | 0.157 | Phosphodiesterase VI inhibitor | 0.157 0.006 DBMET02059 | DBMET02059 | |
| 0.061 | 0.04 | 0.061 | Enoyl-[acyl-carrier-protein] reductase inhibitor | |||
| 0.15 | 0.129 | 0.15 | EphB2 antagonist | |||
| 0.074 | 0.052 | 0.074 | Vanilloid antagonist | |||
| 0.026 | 0.005 | 0.026 | Alpha 2b adrenoreceptor agonist | |||
| 0.057 | 0.037 | 0.057 | Acetyl-CoA transferase 2 inhibitor | |||
| 0.088 | 0.068 | 0.088 | MAO B inhibitor | |||
| 0.068 | 0.048 | 0.099 | Carbonic anhydrase VA inhibitor | 0.099 0.025 DBMET02060 | DBMET02060 | |
| 0.036 | 0.016 | 0.036 | Estrogen-related receptor beta antagonist | |||
| 0.053 | 0.033 | 0.082 | Glucose-6-phosphate translocase inhibitor | 0.082 0.01 DBMET02059 | DBMET02059 | |
| 0.078 | 0.059 | 0.078 | Phosphodiesterase 3A inhibitor | |||
| 0.025 | 0.006 | 0.025 | Purinergic P2Y1 antagonist | |||
| 0.025 | 0.006 | 0.025 | Alpha 2a adrenoreceptor agonist | |||
| 0.101 | 0.083 | 0.101 | Nav1.5 sodium channel blocker | 0.097 0.092 DBMET02060 | ||
| 0.045 | 0.027 | 0.045 | Glutamate (mGluR4) antagonist | |||
| 0.097 | 0.079 | 0.097 | Protein kinase (CK2) alpha inhibitor | |||
| 0.054 | 0.036 | 0.054 | GABA A receptor antagonist | |||
| 0.055 | 0.038 | 0.055 | GABA receptor antagonist | |||
| 0.044 | 0.027 | 0.044 | Heme oxygenase inhibitor | |||
| 0.022 | 0.005 | 0.022 | CC chemokine 9 receptor antagonist | |||
| 0.06 | 0.044 | 0.06 | 5 Hydroxytryptamine 5A antagonist | |||
| 0.033 | 0.017 | 0.033 | Liver X receptor beta antagonist | |||
| 0.061 | 0.045 | 0.061 | Corticotropin releasing factor 2 receptor antagonist | |||
| 0.073 | 0.057 | 0.073 | Vanilloid 4 agonist | |||
| 0.055 | 0.039 | 0.055 | Dihydroorotate oxidase inhibitor | |||
| 0.029 | 0.014 | 0.029 | CXC chemokine 2 receptor antagonist | |||
| 0.065 | 0.05 | 0.065 | CDC7 inhibitor | |||
| 0.043 | 0.029 | 0.043 | GABA B receptor antagonist | |||
| 0.053 | 0.038 | 0.073 | NMDA 2B receptor antagonist | 0.073 0.024 DBMET02060 | DBMET02060 | |
| 0.082 | 0.067 | 0.082 | Hematopoietic | |||
| 0.031 | 0.016 | 0.031 | Purinergic P2Y15 antagonist | |||
| 0.056 | 0.041 | 0.056 | Leukotriene C antagonist | |||
| 0.039 | 0.024 | 0.039 | Glutamate (mGluR8) agonist | |||
| 0.036 | 0.021 | 0.036 | 1-Alkyl-2-acetylglycerophosphocholine esterase inhibitor | |||
| 0.056 | 0.043 | 0.056 | 5 Hydroxytryptamine 5 antagonist | |||
| 0.048 | 0.035 | 0.048 | Plasminogen activator inhibitor antagonist | |||
| 0.107 | 0.094 | 0.223 | Cyclooxygenase 3 inhibitor | 0.223 0.013 DBMET02059 | DBMET02059 | |
| 0.018 | 0.005 | 0.018 | Egl nine homolog 3 inhibitor | |||
| 0.026 | 0.014 | 0.026 | Estradiol 17 beta-dehydrogenase 1 inhibitor | |||
| 0.053 | 0.041 | 0.12 | Glucosylceramidase inhibitor | 0.12 0.005 DBMET02059 | DBMET02059 | |
| 0.029 | 0.017 | 0.029 | Estrogen-related receptor gamma antagonist | |||
| 0.027 | 0.016 | 0.027 | Prostaglandin H2 antagonist | |||
| 0.097 | 0.085 | 0.112 | Interleukin 1b antagonist | 0.112 0.069 DBMET02059 | DBMET02059 | |
| 0.096 | 0.084 | 0.149 | Mucolytic | 0.149 0.033 DBMET02059 | DBMET02059 | |
| 0.056 | 0.045 | 0.056 | Sphingosine 1-phosphate receptor 3 antagonist | |||
| 0.025 | 0.013 | 0.025 | Dopamine D1 agonist | |||
| 0.053 | 0.042 | 0.053 | Cyclin B2 inhibitor | |||
| 0.075 | 0.065 | 0.128 | Glycine receptor antagonist | 0.128 0.014 DBMET02059 0.073 0.069 DBMET02060 | DBMET02059 | |
| 0.051 | 0.041 | 0.051 | Nicotinic alpha3beta2 receptor antagonist | |||
| 0.069 | 0.059 | 0.178 | Carbonic anhydrase XIII inhibitor | 0.178 0.017 DBMET02059 0.147 0.022 DBMET02060 | DBMET02059 | |
| 0.036 | 0.026 | 0.036 | Inosine monophosphate dehydrogenase inhibitor | |||
| 0.071 | 0.061 | 0.071 | Potassium channel (Tandem pore domain) blocker | |||
| 0.061 | 0.051 | 0.061 | Phosphodiesterase III inhibitor | |||
| 0.028 | 0.018 | 0.028 | Hedgehog signaling activator | |||
| 0.066 | 0.056 | 0.066 | Benzodiazepine agonist | |||
| 0.057 | 0.048 | 0.057 | Potassium channel intermediate-conductance Ca-activated blocker | |||
| 0.046 | 0.037 | 0.046 | Benzodiazepine antagonist | |||
| 0.033 | 0.024 | 0.033 | Estrogen receptor alpha agonist | |||
| 0.097 | 0.087 | 0.097 | CDC-like kinase 3 inhibitor | |||
| 0.064 | 0.055 | 0.064 | Glutamate (mGluR6) antagonist | |||
| 0.127 | 0.118 | 0.127 | Protein kinase (CK1) gamma 3 inhibitor | |||
| 0.069 | 0.061 | 0.132 | Na+ K+ transporting ATPase inhibitor | 0.132 0.011 DBMET02059 | DBMET02059 | |
| 0.059 | 0.051 | 0.059 | Histone deacetylase SIRT3 inhibitor | |||
| 0.061 | 0.053 | 0.11 | Carbonic anhydrase V inhibitor | 0.11 0.024 DBMET02060 | DBMET02060 | |
| 0.099 | 0.091 | 0.099 | Histone deacetylase class III inhibitor | |||
| 0.02 | 0.012 | 0.03 | Antibiotic Anthracycline-like | 0.03 0.004 DBMET02059 | DBMET02059 | |
| 0.021 | 0.013 | 0.021 | Steroid 17-alpha-hydroxylase/17,20 lyase inhibitor | |||
| 0.029 | 0.021 | 0.029 | MAP3K8 inhibitor | |||
| 0.12 | 0.113 | 0.12 | Protein-tyrosine phosphatase inhibitor | |||
| 0.069 | 0.063 | 0.069 | GABA aminotransferase inhibitor | |||
| 0.193 | 0.186 | 0.574 | Antithrombotic | 0.574 0.019 DBMET02059 0.245 0.13 DBMET02060 | DBMET02059 | |
| 0.047 | 0.041 | 0.047 | Lysophosphatidic acid 3 receptor antagonist | |||
| 0.058 | 0.052 | 0.058 | Dopamine D1 antagonist | |||
| 0.064 | 0.058 | 0.064 | MDM2 inhibitor | |||
| 0.05 | 0.045 | 0.05 | Phosphodiesterase 4C inhibitor | |||
| 0.054 | 0.048 | 0.054 | Carbonic anhydrase stimulant | |||
| 0.129 | 0.124 | 0.129 | Antipruritic | |||
| 0.064 | 0.059 | 0.064 | Transforming growth factor antagonist | |||
| 0.033 | 0.028 | 0.033 | Nicotinic acid receptor agonist | |||
| 0.025 | 0.02 | 0.025 | Thyroid hormone agonist | |||
| 0.034 | 0.029 | 0.034 | Glutamate (mGluR3) antagonist | |||
| 0.032 | 0.027 | 0.032 | Estradiol 17 beta-dehydrogenase 2 inhibitor | |||
| 0.029 | 0.025 | 0.029 | HCV NS5B polymerase inhibitor | |||
| 0.037 | 0.033 | 0.037 | CDK5/p25 inhibitor | |||
| 0.026 | 0.022 | 0.07 | Uridine phosphorylase inhibitor | 0.07 0.004 DBMET02059 | DBMET02059 | |
| 0.059 | 0.055 | 0.059 | Sphingosine 1-phosphate receptor 4 agonist | |||
| 0.032 | 0.028 | 0.047 | Phosphoglycerate kinase inhibitor | 0.047 0.015 DBMET02059 | DBMET02059 | |
| 0.109 | 0.105 | 0.399 | Protein kinase stimulant | 0.399 0.008 DBMET02059 | DBMET02059 | |
| 0.053 | 0.05 | 0.053 | Bombesin 1 receptor agonist | |||
| 0.144 | 0.141 | 0.144 | Focal adhesion kinase 2 inhibitor | |||
| 0.074 | 0.071 | 0.074 | Glutathione S-transferase inhibitor | |||
| 0.059 | 0.056 | 0.059 | Neuronal nicotinic receptor antagonist | |||
| 0.026 | 0.023 | 0.026 | Nicotinic alpha4beta2 receptor agonist | |||
| 0.109 | 0.106 | 0.109 | Protein kinase C nu inhibitor | |||
| 0.046 | 0.043 | 0.046 | Squalene epoxidase inhibitor | |||
| 0.02 | 0.017 | 0.02 | Glutaminyl-peptide cyclotransferase inhibitor | |||
| 0.034 | 0.031 | 0.034 | Tryptophan 5 hydroxylase inhibitor | |||
| 0.039 | 0.036 | 0.039 | Histamine H2 receptor agonist | |||
| 0.027 | 0.024 | 0.027 | 5 Hydroxytryptamine 6 agonist | |||
| 0.035 | 0.033 | 0.035 | Potassium channel Kv1.1 blocker | |||
| 0.036 | 0.034 | 0.036 | Estradiol 17 beta-dehydrogenase inhibitor | |||
| 0.033 | 0.031 | 0.033 | NMDA receptor subunit 3A antagonist | |||
| 0.019 | 0.018 | 0.019 | Aggrecanase 2 inhibitor | |||
| 0.051 | 0.049 | 0.051 | Alpha 1 adrenoreceptor agonist | |||
| 0.024 | 0.023 | 0.028 | Complement factor 1s inhibitor | 0.028 0.011 DBMET02060 | DBMET02060 | |
| 0.097 | 0.096 | 0.108 | Microtubule formation inhibitor | 0.108 0.077 DBMET02059 | DBMET02059 | |
| 0.03 | 0.029 | 0.03 | Liver X receptor beta agonist | |||
| 0.097 | 0.096 | 0.097 | Caspase 3 inhibitor | |||
| 0.085 | 0.085 | 0.152 | Interleukin 12 antagonist | 0.152 0.012 DBMET02059 | DBMET02059 | |
| 0.041 | 0.042 | 0.042 | Glutamate (mGluR5) agonist | 0.042 0.04 DBMET02060 | DBMET02060 | |
| 0.041 | 0.045 | 0.123 | Carbonic anhydrase XIV inhibitor | 0.123 0.007 DBMET02059 | DBMET02059 | |
| 0.129 | 0.133 | 0.474 | Platelet adhesion inhibitor | 0.394 0.012 DBMET02059 0.474 0.006 DBMET02060 | DBMET02060 | |
| 0.031 | 0.036 | 0.056 | Ceramide glucosyltransferase inhibitor | 0.056 0.005 DBMET02059 | DBMET02059 | |
| 0.038 | 0.045 | 0.062 | Estrogen agonist | 0.062 0.029 DBMET02060 | DBMET02060 | |
| 0.15 | 0.157 | 0.327 | Vasodilator | 0.327 0.04 DBMET02059 | DBMET02059 | |
| 0.023 | 0.033 | 0.03 | Thymidine kinase (Herpes simplex virus 1) inhibitor | 0.027 0.017 DBMET02059 0.03 0.012 DBMET02060 | DBMET02060 | |
| 0.014 | 0.025 | 0.024 | Adenosine kinase inhibitor | 0.024 0.013 DBMET02059 | DBMET02059 | |
| 0.007 | 0.018 | 0.013 | Purinergic P2Y2 agonist | 0.013 0.004 DBMET02059 | DBMET02059 | |
| 0.017 | 0.028 | 0.024 | Glutamate (mGluR1a) agonist | 0.024 0.014 DBMET02060 | DBMET02060 | |
| 0.021 | 0.033 | 0.156 | Sodium/glucose cotransporter 2 inhibitor | 0.156 0.001 DBMET02059 | DBMET02059 | |
| 0.013 | 0.025 | 0.031 | Telomerase stimulant | 0.031 0.003 DBMET02059 | DBMET02059 | |
| 0.022 | 0.034 | 0.024 | Thymidine phosphorylase inhibitor | 0.024 0.023 DBMET02059 | DBMET02059 | |
| 0.021 | 0.034 | 0.221 | Sodium/glucose cotransporter inhibitor | 0.221 0.001 DBMET02059 | DBMET02059 | |
| 0.033 | 0.047 | 0.045 | Thymidine kinase inhibitor | 0.045 0.023 DBMET02059 0.042 0.027 DBMET02060 | DBMET02059 | |
| 0.02 | 0.034 | 0.043 | Vanilloid 2 agonist | 0.043 0.004 DBMET02059 0.027 0.014 DBMET02060 | DBMET02059 | |
| 0.054 | 0.072 | 0.133 | Interferon inducer | 0.133 0.005 DBMET02059 | DBMET02059 | |
| 0.043 | 0.067 | 0.112 | Heparanase inhibitor | 0.112 0.003 DBMET02059 0.058 0.026 DBMET02060 | DBMET02059 | |
| 0.121 | 0.146 | 0.273 | Interleukin 6 antagonist | 0.273 0.019 DBMET02059 | DBMET02059 | |
| 0.062 | 0.09 | 0.174 | Interferon agonist | 0.174 0.008 DBMET02059 | DBMET02059 | |
| 0.082 | 0.11 | 0.196 | DNA polymerase I inhibitor | 0.196 0.029 DBMET02059 | DBMET02059 | |
| 0.013 | 0.042 | 0.024 | Hypoxanthine phosphoribosyltransferase inhibitor | 0.024 0.023 DBMET02059 | DBMET02059 | |
| 0.008 | 0.038 | 0.025 | Ileal bile acid transport inhibitor | 0.025 0.006 DBMET02059 | DBMET02059 | |
| 0.039 | 0.074 | 0.228 | Alpha-mannosidase inhibitor | 0.228 0.003 DBMET02059 | DBMET02059 | |
| 0.073 | 0.108 | 0.242 | Expectorant | 0.242 0.014 DBMET02059 | DBMET02059 | |
| 0.03 | 0.066 | 0.234 | Mannosidase inhibitor | 0.234 0.003 DBMET02059 | DBMET02059 | |
| 0.098 | 0.141 | 0.129 | Diuretic | 0.129 0.095 DBMET02060 | DBMET02060 | |
| 0.043 | 0.097 | 0.062 | Adenine nucleotide translocase inhibitor | 0.062 0.025 DBMET02059 | DBMET02059 | |
| 0.007 | 0.061 | 0.309 | Cholecystokinin A agonist | 0.309 0.002 DBMET02060 | DBMET02060 | |
| 0.022 | 0.082 | 0.167 | Phosphorylase inhibitor | 0.167 0.006 DBMET02059 | DBMET02059 | |
| 0.228 | 0.294 | 0.763 | Antiinflammatory | 0.763 0.02 DBMET02059 0.654 0.04 DBMET02060 | DBMET02059 | |
| 0.022 | 0.092 | 0.047 | Antimetabolite | 0.047 0.033 DBMET02059 | DBMET02059 | |
| 0.102 | 0.173 | 0.429 | Nitric oxide antagonist | 0.429 0.022 DBMET02059 0.177 0.078 DBMET02060 | DBMET02059 | |
| 0.007 | 0.078 | 0.574 | Cholecystokinin agonist | 0.574 0.002 DBMET02060 | DBMET02060 | |
| 0.065 | 0.141 | 0.119 | Adenylate cyclase inhibitor | 0.119 0.069 DBMET02059 | DBMET02059 | |
| 0.115 | 0.195 | 0.464 | Immunostimulant | 0.464 0.034 DBMET02059 | DBMET02059 | |
| 0.014 | 0.095 | 0.058 | Carbonic anhydrase XII inhibitor | 0.058 0.034 DBMET02059 | DBMET02059 | |
| 0.153 | 0.234 | 0.387 | Angiogenesis inhibitor | 0.286 0.1 DBMET02059 0.387 0.057 DBMET02060 | DBMET02060 | |
| 0.141 | 0.223 | 0.355 | Peptidyltransferase inhibitor | 0.355 0.011 DBMET02059 | DBMET02059 | |
| 0.057 | 0.141 | 0.095 | Aminoacyl-tRNA synthetase inhibitor | 0.095 0.051 DBMET02059 | DBMET02059 | |
| 0.021 | 0.108 | 0.055 | Leukocyte elastase inhibitor | 0.055 0.021 DBMET02060 | DBMET02060 | |
| 0.076 | 0.164 | 0.27 | Thrombolytic | 0.27 0.029 DBMET02059 0.218 0.044 DBMET02060 | DBMET02059 | |
| 0.023 | 0.115 | 0.035 | Adenosine uptake inhibitor | 0.035 0.023 DBMET02060 | DBMET02060 | |
| 0.002 | 0.097 | 0.013 | Purinergic P2 agonist | 0.013 0.012 DBMET02059 | DBMET02059 | |
| 0.002 | 0.097 | 0.013 | Purinergic receptor agonist | 0.013 0.012 DBMET02059 | DBMET02059 | |
| 0.019 | 0.116 | 0.051 | Aldose reductase inhibitor | 0.051 0.038 DBMET02059 0.051 0.038 DBMET02060 | DBMET02060 | |
| 0.034 | 0.135 | 0.054 | Factor III inhibitor | 0.054 0.026 DBMET02059 | DBMET02059 | |
| 0.064 | 0.167 | 0.105 | T cell inhibitor | 0.105 0.02 DBMET02059 | DBMET02059 | |
| 0.041 | 0.145 | 0.059 | Lipocortins synthesis agonist | 0.059 0.039 DBMET02059 | DBMET02059 | |
| 0.058 | 0.163 | 0.094 | Interleukin 5 antagonist | 0.094 0.049 DBMET02059 | DBMET02059 | |
| 0.019 | 0.127 | 0.058 | Carbonic anhydrase inhibitor | 0.058 0.048 DBMET02060 | DBMET02060 | |
| 0.039 | 0.154 | 0.066 | MAP kinase kinase 10 inhibitor | 0.066 0.047 DBMET02060 | DBMET02060 | |
| 0.034 | 0.153 | 0.07 | Cathepsin G inhibitor | 0.07 0.054 DBMET02060 | DBMET02060 | |
| 0.025 | 0.145 | 0.192 | Antineoplastic antibiotic | 0.192 0.022 DBMET02059 | DBMET02059 | |
| 0.031 | 0.168 | 0.059 | DNA gyrase inhibitor | 0.059 0.051 DBMET02059 | DBMET02059 | |
| 0.144 | 0.288 | 0.557 | Apoptosis antagonist | 0.557 0.014 DBMET02059 | DBMET02059 | |
| 0.046 | 0.192 | 0.131 | ATPase (Vacuolar H+) inhibitor | 0.131 0.014 DBMET02059 | DBMET02059 | |
| 0.016 | 0.169 | 0.491 | Cholecystokinin B agonist | 0.491 0.002 DBMET02060 | DBMET02060 | |
| 0.066 | 0.219 | 0.672 | Angiogenesis stimulant | 0.672 0.005 DBMET02059 0.605 0.006 DBMET02060 | DBMET02059 | |
| 0.052 | 0.209 | 0.201 | Transcription factor NF kappa B stimulant | 0.201 0.009 DBMET02059 | DBMET02059 | |
| 0.01 | 0.167 | 0.079 | Protein 30S ribosomal subunit inhibitor | 0.079 0.004 DBMET02059 | DBMET02059 | |
| 0.05 | 0.225 | 0.172 | Multidrug resistance-associated protein 1 inhibitor | 0.172 0.017 DBMET02060 | DBMET02060 | |
| 0.083 | 0.261 | 0.236 | Platelet antagonist | 0.236 0.079 DBMET02059 0.236 0.079 DBMET02060 | DBMET02060 | |
| 0.076 | 0.258 | 0.427 | Hepatoprotectant | 0.427 0.011 DBMET02059 0.179 0.081 DBMET02060 | DBMET02059 | |
| 0.019 | 0.202 | 0.407 | Selectin antagonist | 0.407 0.003 DBMET02059 0.302 0.005 DBMET02060 | DBMET02059 | |
| 0.077 | 0.261 | 0.255 | Insulin secretagoues | 0.255 0.019 DBMET02059 | DBMET02059 | |
| 0.005 | 0.199 | 0.272 | Cholecystokinin A antagonist | 0.272 0.004 DBMET02060 | DBMET02060 | |
| 0.006 | 0.201 | 0.017 | O6-alkylguanine-DNA alkyltransferase inhibitor | 0.017 0.011 DBMET02059 | DBMET02059 | |
| 0.001 | 0.196 | 0.013 | Antibiotic Macrolide-like | 0.013 0.011 DBMET02059 | DBMET02059 | |
| 0.004 | 0.2 | 0.031 | Estrone sulfatase inhibitor | 0.031 0.01 DBMET02060 | DBMET02060 | |
| 0.045 | 0.242 | 0.117 | DNA directed RNA polymerase inhibitor | 0.117 0.039 DBMET02060 | DBMET02060 | |
| 0.009 | 0.206 | 0.058 | Factor Xa inhibitor | 0.058 0.025 DBMET02060 | DBMET02060 | |
| 0.016 | 0.217 | 0.102 | 5 Hydroxytryptamine 1F antagonist | 0.102 0.03 DBMET02060 | DBMET02060 | |
| 0.135 | 0.341 | 0.486 | Interleukin 2 agonist | 0.486 0.01 DBMET02059 | DBMET02059 | |
| 0.05 | 0.259 | 0.194 | Toll-Like receptor 4 antagonist | 0.194 0.007 DBMET02059 | DBMET02059 | |
| 0.004 | 0.23 | 0.02 | Sodium/hydrogen exchanger inhibitor | 0.02 0.009 DBMET02060 | DBMET02060 | |
| 0.005 | 0.265 | 0.03 | Adenosine A1 receptor agonist | 0.03 0.012 DBMET02059 | DBMET02059 | |
| 0.045 | 0.322 | 0.248 | Cell adhesion inhibitor | 0.202 0.024 DBMET02059 0.248 0.015 DBMET02060 | DBMET02060 | |
| 0.085 | 0.367 | 0.5 | Immunosuppressant | 0.5 0.033 DBMET02059 | DBMET02059 | |
| 0.005 | 0.286 | 0.195 | Cholecystokinin antagonist | 0.195 0.005 DBMET02060 | DBMET02060 | |
| 0.006 | 0.3 | 0.043 | 1,3-Beta-glucan synthase inhibitor | 0.03 0.016 DBMET02059 0.043 0.004 DBMET02060 | DBMET02060 | |
| 0.006 | 0.308 | 0.022 | Motilin receptor agonist | 0.022 0.017 DBMET02059 | DBMET02059 | |
| 0.075 | 0.378 | 0.631 | Hypoglycemic | 0.631 0.007 DBMET02059 | DBMET02059 | |
| 0.04 | 0.346 | 0.08 | Vanilloid agonist | 0.08 0.071 DBMET02060 | DBMET02060 | |
| 0.016 | 0.323 | 0.061 | Nitric oxide donor | 0.061 0.046 DBMET02059 | DBMET02059 | |
| 0.013 | 0.33 | 0.113 | Protein 50S ribosomal subunit inhibitor | 0.113 0.01 DBMET02059 | DBMET02059 | |
| 0.084 | 0.413 | 0.459 | Immunomodulator | 0.459 0.029 DBMET02059 | DBMET02059 | |
| 0.004 | 0.379 | 0.151 | Cholecystokinin B antagonist | 0.151 0.004 DBMET02060 | DBMET02060 | |
| 0.024 | 0.4 | 0.301 | Cell adhesion molecule inhibitor | 0.075 0.06 DBMET02059 0.301 0.005 DBMET02060 | DBMET02060 | |
| 0.033 | 0.447 | 0.173 | Hypolipemic | 0.173 0.115 DBMET02059 | DBMET02059 | |
| 0.004 | 0.419 | 0.06 | Factor XI inhibitor | 0.06 0.007 DBMET02060 | DBMET02060 | |
| 0.076 | 0.544 | 0.805 | Cyclophilin D inhibitor | 0.805 0.006 DBMET02059 | DBMET02059 | |
| 0.012 | 0.481 | 0.1 | Antibiotic Aminoglycoside-like | 0.1 0.003 DBMET02059 | DBMET02059 | |
| 0.005 | 0.52 | 0.08 | Factor XIa inhibitor | 0.08 0.008 DBMET02060 | DBMET02060 | |
| 0.044 | 0.56 | 0.286 | Antiobesity | 0.255 0.151 DBMET02059 0.286 0.126 DBMET02060 | DBMET02060 | |
| 0.01 | 0.542 | 0.035 | Toll-Like receptor 4 agonist | 0.035 0.007 DBMET02059 0.026 0.02 DBMET02060 | DBMET02059 | |
| 0.013 | 0.632 | 0.6 | Anticoagulant | 0.6 0.006 DBMET02060 | DBMET02060 | |
| 0.007 | 0.689 | 0.112 | Thrombin inhibitor | 0.112 0.02 DBMET02060 | DBMET02060 | |
| 0.005 | 0.714 | 0.135 | Elastase inhibitor | 0.135 0.005 DBMET02060 | DBMET02060 | Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |